GliaPharm: Funding, Investors & Team (Sep 2026)
GliaPharm is a Swiss-based biotechnology organization that offers medicines for neurological and mental problems. GliaPharm's imaginative helpful methodology is to target glial cells , the 'support cells' of neurons, to maintain and improve cerebrum digestion in obsessive circumstances. Their vision is to turn into a main biotechnology organization with an emphasis on glia-intervened pathways as specialists for neuroprotection and upkeep of mental capabilities. GliaPharm is a Swiss biotechnology organization dynamic in the improvement of medicines for neurological and mental illnesses. The inventive helpful methodology of GliaPharm is to target glial cells , or 'support cells' of neurons, to help and further develop cerebrum digestion under specific obsessive circumstances. Their vision is to turn into a forerunner in the improvement of glial cell focusing on specialists that go about as neuroprotective specialists and keep up with mental capabilities.
GliaPharm has raised $6.3M across 4 funding rounds on record, the most recent an undisclosed round announced in Sep 2024.
GliaPharm Company Profile and Key Stats
Latest funding round on record: Sep 2024.
GliaPharm Funding Rounds
1 of 4 rounds was announced without a disclosed amount and is excluded from the total.
GliaPharm raised $2.0M in an undisclosed round announced in May 2020.
2.2 years later, a Debt Financing of $100k was announced in Jul 2022.
1.4 years later, an undisclosed round of $4.2M was announced in Dec 2023.
9 months later, an undisclosed round was announced in Sep 2024 with no disclosed amount.
GliaPharm Founders and Leadership Team
Contact details for the GliaPharm team: 1 of 2 have an email address on file.
Start 14-day free trial →GliaPharm Funding Compared to Other Biotechnology Startups
Funded Startups Like GliaPharm in Biotechnology and Geneva
Companies Similar to GliaPharm
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
GliaPharm Funding FAQs
What does GliaPharm do?
GliaPharm is a Swiss-based biotechnology organization that offers medicines for neurological and mental problems. GliaPharm's imaginative helpful methodology is to target glial cells , the 'support cells' of neurons, to maintain and improve cerebrum digestion in obsessive circumstances. Their vision is to turn into a main biotechnology organization with an emphasis on glia-intervened pathways as specialists for neuroprotection and upkeep of mental capabilities. GliaPharm is a Swiss biotechnology organization dynamic in the improvement of medicines for neurological and mental illnesses. The inventive helpful methodology of GliaPharm is to target glial cells , or 'support cells' of neurons, to help and further develop cerebrum digestion under specific obsessive circumstances. Their vision is to turn into a forerunner in the improvement of glial cell focusing on specialists that go about as neuroprotective specialists and keep up with mental capabilities.
How much funding has GliaPharm raised?
GliaPharm has raised $6.3M across 4 rounds on record.
When did GliaPharm last raise funding?
GliaPharm's most recent funding round on record was announced in Sep 2024. The amount was not disclosed.
Who founded GliaPharm?
FundedIQ lists Ambroise Magistretti (Founder) at GliaPharm.
Who is the CEO of GliaPharm?
Sylvain Lengacher is listed as CEO at GliaPharm.
Where is GliaPharm headquartered?
GliaPharm is based in Geneva, Geneve, Switzerland.
How many employees does GliaPharm have?
GliaPharm is in the 11-50 employee band.
About FundedIQ's GliaPharm Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for GliaPharm is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.